Anti-doping testing comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-05. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
==== Constituents ==== A 2013 review described sulfated polysaccharides synthesized by 120 marine microalgae, most of which are EPS. These heteropolymers consist mainly of galactose, glucose, and xylose in different proportions except those from Gyrodinium impudicum, which are homopolymers. Most EPS from cyanobacteria are also complex anionic heteropolymers containing six to ten different monosaccharides, one or more uronic acids, and various functional substituents such as methyl, acetate, pyruvate, sulfate groups, and proteins. For instance, the EPS from Arthrospira platensis are heteropolymer with protein (55%) moieties and a complex polysaccharide composition, containing seven neutral sugars: glucose, rhamnose, fructose, galactose, xylose, arabinose, and mannose, as well as two uronic acids, galacturonic acid and glucuronic acid. Dunaliella salina is a unicellular green alga of outstanding halotolerance. Salt stress induces the secretion of extracellular polymeric substances from D. salina. It is speculated that the release of complex mixtures of macromolecular polyelectrolytes with high polysaccharide content contributes to the survival strategy of D. salina in varying salt concentrations. Four monosaccharides (galactose, glucose, xylose, and fructose) were detected in the hydrolysate of EPS from D. salina under salt stress. In contrast, the water-soluble polysaccharides released by Chlorella pyrenoidosa contain galactose, arabinose, mannose, ribose, xylose, fucose, and rhamnose; their release depends on the cell photosynthetic activity and reproductive state.
=== RNAi therapeutics === Just after Fire and Mello's ground-breaking discovery, Elbashir et al. discovered, by using synthetically made siRNA, it was possible to target the silencing of specific sequences in a gene, rather than silencing the entire gene. Only a year later, McCaffrey and colleagues demonstrated that this sequence-specific silencing had therapeutic applications by targeting a sequence from the Hepatitis C virus in transgenic mice. Since then, multiple researchers have been attempting to expand the therapeutic applications of RNAi, specifically looking to target genes that cause various types of cancer. By 2006, the first applications to reach clinical trials were in the treatment of macular degeneration and respiratory syncytial virus. Four years later the first-in-human Phase I clinical trial was started, using a nanoparticle delivery system to target solid tumors. The FDA approved the first siRNA-based drug (patisiran) in 2018. Givosiran and lumasiran later won FDA approval for the treatment of AHP and PH1 in 2019 and 2020, respectively. Inclisiran received EMA approval in 2020 for the treatment of high cholesterol and is currently under review by the FDA.
== Clinical significance == Increasing evidence links aberrant CL metabolism and content to human disease. Human conditions include neurological disorders, cancer, and cardiovascular and metabolic disorders (a full list can be found at). As the number of human diseases with CL profile abnormalities has exponentially grown, the use of qualitative and quantitative diagnostics has emerged as a necessity.
=== Divisions and global locations === Ajinomoto currently operates separate divisions for North America, Latin America, and Asia, with Europe, the Middle East, and Africa being combined into the EMEA division. Ajinomoto also owns dozens of subsidiaries globally for its food, biochemical, and healthcare businesses.
Sources: en.wikipedia.org
=== Mic–Mu === Leonor Michaelis (1875–1949). German biochemist at the Rockefeller Institute of Medical Research, known for early work on enzyme kinetics. He developed biochemistry in Japan. He studied quinones, and used this knowledge to develop a method for producing a perm (hairstyle). Friedrich Miescher (1844–1895). Swiss physician and biologist at Leipzig University, the first to isolate DNA. Kenneth R. Miller (born 1948), American evolutionary biologist and author of Finding Darwin's God César Milstein FRS (1927–2002). Argentinian-British biochemist at the University of Cambridge, known for developing the use of monoclonal antibodies. Nobel Prize in Physiology or Medicine (1984). Foreign associate Natl. Acad. Sci. USA. María Teresa Miras Portugal (1948–2021), Spanish biochemist, pharmacist and molecular biologist. Peter D. Mitchell FRS (1920–1992). British biochemist at Glynn Research, known for the theory of chemiosmosis. Nobel Prize in Chemistry (1978). Foreign associate Natl. Acad. Sci. USA. John Keith Moffat (b. 1943), British biophysicist at Argonne National Laboratory known for work on time-resolved crystallography. Catherine Anne Money (b. 1940), Australian biochemist known for revolutionizing leather production Jacques Monod FRS (foreign member) (1910–1976). French biochemist and microbiologist at the Pasteur Institute, known for many discoveries and for the theory of allostery. His philosophical book Chance and Necessity has been influential. Nobel Prize in Physiology or Medicine (1965).
=== Age === Age estimation attempts to determine the skeletal/biological age-at-death. The primary assumption is that an individual's skeletal age is closely associated with their chronological age. Age estimation can be based on patterns of growth and development or degenerative changes in the skeleton. A variety of skeletal series methods to assess these types of changes have been developed. For instance, in children age is typically estimated by assessing dental development, ossification and fusion of specific skeletal elements, or long bone length. For children, different teeth erupt from the gums serially are the most reliable for telling a child's age. However, fully developed teeth are less indicative. In adults, degenerative changes to the pubic symphysis, the auricular surface of the ilium, the sternal end of the 4th rib, and dental attrition are commonly used to estimate skeletal age. Until the age of about 30, human bones keep growing. Different bones fuse at different points of growth. This development can vary across individuals. Wear and tear on bones further complicates age estimates. Often, estimates are limited to 'young' (20–35 years), 'middle' (35–50 years), or 'old' (50+ years).
In November 2007, Merck agreed to pay $4.85 billion to settle most of the pending Vioxx lawsuits. The settlement required that claimants provide medical and pharmacy records confirming the occurrence of a heart attack, ischemic stroke, or sudden cardiac death; the receipt of at least 30 Vioxx pills within 60 days prior to the injury or death; and confirmation of Vioxx being used within 14 days of the Vioxx-related event. The settlement was generally viewed by industry analysts and investors as a victory for Merck, considering that original estimates of Merck's liability reached between $10 billion and $25 billion. As of mid-2008, when the plaintiff class had reached the threshold percentage required by Merck to go through with the settlement, plaintiffs had prevailed in only three of the twenty cases that had reached juries, all with relatively small awards. Merck has refused to consider compensation for Vioxx victims and their families outside the US. This is particularly true in the UK where there are at least 400 victims and the legal protection afforded to the victims and their families is particularly weak. According to internal e-mail traffic released at a later lawsuit, Merck had a list of doctors critical of Vioxx to be "neutralized" or "discredited". "We may need to seek them out and destroy them where they live," wrote an employee. A Stanford Medical School professor said that Merck was engaged in intimidation of researchers and infringement upon academic freedom.
While most hormonal therapy strategies seek to block hormone signalling to cancer cells, there are some instances in which supplementation with specific hormone agonists may have a growth-inhibiting, or even cytotoxic effect on tumor cells. Because many hormones can produce antagonism and feedback inhibition of the synthesis of other hormones, there is significant overlap between this concept and those discussed above.
== Music == A musicologist, disciple and collaborator of Dom Prosper Guéranger, Dom Pothier contributed to the reconstitution, the restoration and the renewal of the Gregorian chant, a form of monophonic, unaccompanied sacred song of the Roman Catholic Church. Besides being the composer of many Gregorian songs (Officium Defunctorum, 1887) and the writer of a huge number of articles, Dom Pothier was also the head and editor of the Revue du Chant Grégorien (1892–1914) - supervising the publication of several works (Hymnes, Christmas office, Antifonario, Cantus mariales) -, the founder of the Paléographie Musicale publication for the dissemination of medieval liturgical manuscripts, and the author of a new edition of the choir books based on manuscripts of the Gregorian chant and of several studies on the plainchant, including Les mélodies grégoriennes d'après la tradition (Gregorian Melodies According to the Tradition), 1880, his chief work which became the standard work on the subject. Dom Pothier was appointed president of the newly created Pontifical Commission on the Vatican Edition of the Gregorian Liturgical Books by Pope Pius X in 1904. As chairman of this commission for the reconstitution of the music of the Roman Catholic Mass, Dom Pothier lived in Rome from 1904 till 1913. His Liber Gradualis, 1883, marked the beginning of a reform in liturgical chant and was used as a basis for the Gradual Vatican which was published, under his responsibility, in 1908.
Sources: en.wikipedia.org
GSK-3 functions by phosphorylating a serine or threonine residue on its target substrate. A positively charged pocket adjacent to the active site binds a "priming" phosphate group attached to a serine or threonine four residues C-terminal of the target phosphorylation site. The active site, at residues 181, 200, 97, and 85, binds the terminal phosphate of ATP and transfers it to the target location on the substrate (see figure 1).
In 1809, Karađorđe appealed to an alliance with the Habsburgs and Napoleon, with no success, even wrote personally to Napoleon seeking military assistance, and in 1810, dispatched an emissary to the French Empire. However, the French did not believe that the rebels had the military capacity to defeat the Ottomans or expulse them from the Balkans. In 1812, under pressure from Napoleon, Russia was forced to sign the Treaty of Bucharest, which restored peace with the Ottomans. One of the clauses of the treaty provided for the maintenance of Serbian autonomy, also, a truce was signed according to the Article 8 of the Treaty. Then, the Russians encouraged Karađorđe and his followers to negotiate directly with the Porte.
After the incident, Marine Catering Services issued a reminder to seafarers that the UK Food Act makes it illegal for crews to fish for food from their vessels. In September 2016, a British holidaymaker died while on honeymoon in Mexico after consuming fish contaminated with the toxins. During October 2016, more than 100 people suffered from ciguatera poisoning after eating fish heads supplied by an export firm in Mangalore, India.
=== Radiotherapy === Radiotherapy is used mostly for focal type of NM due to the nature of damage and success rate associated with the treatment. Radiotherapy targets the tumor and destroys the collective tissues of cancerous cells. Proton therapy, which delivers radiation via charged protons rather than X-rays, has recently shown promise as an effective treatment for leptomeningeal disease.
== Further reading == Tirelli, F.; Giraudo, C.; Soliani, M.; Calabrese, F.; Martini, G.; Gisondi, P.; Meneghel, A.; Zulian, Francesco (2023-10-17). "Connective tissue nevus misdiagnosed as juvenile localized scleroderma". Pediatric Rheumatology. 21 (1) 125. Springer Science and Business Media LLC. doi:10.1186/s12969-023-00913-9. ISSN 1546-0096. PMC 10583392. PMID 37848914. Pierard, Gerald E.; Lapiere, Charles M. (1985). "Nevi of connective tissue A reappraisal of their classification". The American Journal of Dermatopathology. 7 (4). Ovid Technologies (Wolters Kluwer Health): 325–334. doi:10.1097/00000372-198508000-00003. ISSN 0193-1091. PMID 3842789.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.